Evidence map›Paper›PMID 26674154›Full record

ArticleWorld journal of gastroenterology2015

Aspartate transaminase to platelet ratio index in hepatitis C virus and Schistosomiasis coinfection.

Moutaz Derbala, Mohammed Elshiekh Elbadri, Aliaa Mohamed Amer, Saad AlKaabi, Khaleel Hassan Sultan, Yasser Medhat Kamel, Eman Hassan Satti Elsayed, Tony Yervant Avades, Prem Chandra, Fatma M Shebl

Open access · bronzeAbstract readComparative StudyEvaluation Study
In one paragraph

Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Moutaz DerbalaMoutaz Derbala, Mohammed Elshiekh Elbadri, Saad AlKaabi, Khaleel Hassan Sultan, Yasser Medhat Kamel, Gastroenterology and Hepatology, Hamad Medical Corporation, Hamad General Hospital, Doha 00974, Qatar.
Mohammed Elshiekh ElbadriMoutaz Derbala, Mohammed Elshiekh Elbadri, Saad AlKaabi, Khaleel Hassan Sultan, Yasser Medhat Kamel, Gastroenterology and Hepatology, Hamad Medical Corporation, Hamad General Hospital, Doha 00974, Qatar.
Aliaa Mohamed AmerMoutaz Derbala, Mohammed Elshiekh Elbadri, Saad AlKaabi, Khaleel Hassan Sultan, Yasser Medhat Kamel, Gastroenterology and Hepatology, Hamad Medical Corporation, Hamad General Hospital, Doha 00974, Qatar.
Saad AlKaabiMoutaz Derbala, Mohammed Elshiekh Elbadri, Saad AlKaabi, Khaleel Hassan Sultan, Yasser Medhat Kamel, Gastroenterology and Hepatology, Hamad Medical Corporation, Hamad General Hospital, Doha 00974, Qatar.
Khaleel Hassan SultanMoutaz Derbala, Mohammed Elshiekh Elbadri, Saad AlKaabi, Khaleel Hassan Sultan, Yasser Medhat Kamel, Gastroenterology and Hepatology, Hamad Medical Corporation, Hamad General Hospital, Doha 00974, Qatar.
Yasser Medhat KamelMoutaz Derbala, Mohammed Elshiekh Elbadri, Saad AlKaabi, Khaleel Hassan Sultan, Yasser Medhat Kamel, Gastroenterology and Hepatology, Hamad Medical Corporation, Hamad General Hospital, Doha 00974, Qatar.
Eman Hassan Satti ElsayedMoutaz Derbala, Mohammed Elshiekh Elbadri, Saad AlKaabi, Khaleel Hassan Sultan, Yasser Medhat Kamel, Gastroenterology and Hepatology, Hamad Medical Corporation, Hamad General Hospital, Doha 00974, Qatar.
Tony Yervant AvadesMoutaz Derbala, Mohammed Elshiekh Elbadri, Saad AlKaabi, Khaleel Hassan Sultan, Yasser Medhat Kamel, Gastroenterology and Hepatology, Hamad Medical Corporation, Hamad General Hospital, Doha 00974, Qatar.
Prem ChandraMoutaz Derbala, Mohammed Elshiekh Elbadri, Saad AlKaabi, Khaleel Hassan Sultan, Yasser Medhat Kamel, Gastroenterology and Hepatology, Hamad Medical Corporation, Hamad General Hospital, Doha 00974, Qatar.
Fatma M SheblMoutaz Derbala, Mohammed Elshiekh Elbadri, Saad AlKaabi, Khaleel Hassan Sultan, Yasser Medhat Kamel, Gastroenterology and Hepatology, Hamad Medical Corporation, Hamad General Hospital, Doha 00974, Qatar.
Hamad General Hospital · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the diagnostic accuracy, of aminotransferase-to-platelet ratio index (APRI) alone and with antischistosomal antibody (Ab) in patients with hepatitis C virus (HCV) and schistosomiasis coinfection.

methodsThis retrospective study included medical records of three hundred and eighty three Egyptian men patients who had undergone percutaneous liver biopsy between January 2006 to April 2014 in tertiary care hospital in Qatar for diagnosis or monitoring purpose were selected. Data of patients > 18 years of age were included in the study. The values of HCV RNA titer and antischistosomal antibody titer were also taken into consideration. Patients were excluded from the study if they had any other concomitant chronic liver disease, including; history of previous antiviral or interferon therapy, immunosuppressive, therapy, chronic hepatitis B infection, human immunodeficiency virus co-infection, autoimmune hepatitis, decompensated liver disease, hepatocellular carcinoma, prior liver transplantation, and if no data about the liver biopsy present.

resultsMedian age of patients was 46 years. About 7.1% had no fibrosis, whereas 30.4%, 37.5%, 20.4%, and 4.6% had fibrosis of stage I, II, III, and IV respectively. In bivariate analysis, APRI score, levels of AST, platelet count and age of patient showed statistically significant association with liver fibrosis (P < 0.0001); whereas antischistosomal antibody titer (P = 0.52) and HCV RNA titer (P = 0.79) failed to show a significant association. The respective AUC values for no fibrosis, significant fibrosis, severe fibrosis and cirrhosis of APRI score were 63%, 73.2%, 81.1% and 88.9% respectively. This showed good sensitivity and specificity of APRI alone for grading of liver fibrosis. But the inclusion of anti-Schistosoma antibody did not improve the prediction of fibrosis stage.

conclusionThe study results suggest that noninvasive biochemical markers like APRI are sensitive and specific in diagnosing the degree of fibrosis and cirrhosis in patients with coinfection of HCV and schistosomiasis as compared to biopsy. The addition of antischistosomal Ab to APRI did not improve sensitivity for predicting the degree of cirrhosis.

Indexed as

Blood PlateletsClinical Enzyme TestsCoinfectionAntibodies, ProtozoanArea Under CurveAspartate AminotransferasesBiomarkersBiopsyEgyptHepatitis CHumansLiver CirrhosisMaleMiddle AgedPlatelet CountPredictive Value of TestsAntibodies, ProtozoanAspartate AminotransferasesBiomarkersRNA, ViralAspartate transaminase to platelet ratio indexHepatitis CLiver biopsyLiver fibrosisSchistosomiasis

Identifiers

PMID26674154
PMCPMC4674732
OpenAlexW2198083123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.